FibroGen Business Model Canvas

FibroGen leverages CMOs for API and finished-dose manufacturing, with partners handling scale-up, GMP-quality control, cold-chain logistics and redundancy to ensure supply continuity; this outsourced model supports flexible capacity for global launches (Evrenzo rollouts) while reducing upfront capex and meeting reliability targets. The global CMO market exceeded $100 billion in 2024, underscoring available capacity.

FibroGen partners with AstraZeneca/Astellas for co-development/co-commercialization of oral anemia drugs, leverages CROs/academic sites for Phase I–III, CMOs for GMP supply (global CMO market >$100B in 2024), and biomarker/advocacy/payor alliances to boost enrollment, reimbursement and real-world uptake (CKD ≈700M; MDS ≈4/100k).

Engage regulators on filings, responses and post-marketing commitments, building on roxadustat’s approvals in China (2018) and Japan (2020) while addressing past FDA safety reviews; maintain timely PSURs and RMPs per ICH and EMA rules. Develop value dossiers and HEOR targeting QALY thresholds (UK NICE £20–30k/QALY) to support reimbursement. Navigate HTA submissions and pricing negotiations, planning typical EU discount ranges of 20–40%.

Discover and optimize HIF/anti‑fibrotic small molecules with GLP tox, CMC and translational PK/PD models to enable INDs. Run global Phase 1–3 programs (Phase 3 >4,000 pts, 20+ countries), manage GCP data, and time pivotal readouts to 2024 regulatory milestones. Engage regulators/HTA (roxadustat approvals CN 2018, JP 2020), build HEOR/market access; scale GMP manufacturing and global distribution aligned with 2024 $1.65T pharma spend.

Experienced teams in nephrology, hematology, oncology and CMC drive FibroGen’s innovation, supporting late‑stage programs such as roxadustat developed in collaboration with AstraZeneca and Astellas.

Regulatory, HEOR and market‑access experts translate clinical data into value, underpinning reimbursement strategies across China, Japan and other markets in 2024.

Clinical operations ensure efficient execution of global trials spanning multiple regions, while medical affairs builds credibility with KOLs to support uptake and guideline engagement.

Robust clinical evidence (8,000+ patients in registrational/extension trials as of 2024) and real‑world studies underpin labeling, HEOR and payer access. Global IP and CMC know‑how secure exclusivity and manufacturing defensibility, enabling royalty and licensing revenue via Astellas and AstraZeneca partnerships. Experienced clinical, regulatory and market‑access teams plus CRO/CMO networks sustain global development and commercialization.

As of 2024 FibroGen advances two late‑stage candidates—roxadustat (HIF stabilizer) and pamrevlumab (anti‑CTGF)—plus multiple earlier programs targeting MDS anemia and cancer‑fibrosis biology. This diversification across distinct mechanisms reduces single‑asset risk and expands potential indications beyond CKD anemia. The multi‑asset pipeline generates sustained newsflow and option value for partners and investors.

Oral noninjectable anemia therapy addresses ~37,000,000 US adults with CKD (2024 CDC) and ~550,000 on dialysis, improving adherence and enabling home care to reduce clinic visits. Dual targeting of dialysis and non‑dialysis CKD and activity in inflammatory/difficult cohorts may lower ESA/rescue use and hospitalizations. As of 2024 FibroGen advances roxadustat and pamrevlumab late‑stage, diversifying risk and indications.

Share robust outcomes data and budget-impact models with payers and HTAs, run outcomes- or value-based pilots where appropriate to de-risk adoption, align on prior-authorization criteria tied to real-world endpoints, and schedule periodic reviews to sustain and expand coverage.

Maintain KOL engagement via congresses, advisory boards and publications; CKD affects ~700 million people in 2024. Deliver patient access, reimbursement navigation, digital adherence and copay/bridge programs to support start and persistence. Share outcomes and budget-impact models with payers; run value-based pilots and align PA criteria. PV: 72h signal triage; 7/15d expedited reporting.

Field sales and MSLs deploy to educate HCPs on therapy positioning and address clinical questions with evidence, targeting the global CKD population of ~700 million (2024) where anemia affects up to 50% of patients. They gather frontline insights to refine messaging and coordinate with access teams to drive pull-through and reimbursement engagement.

Specialty pharmacies, distributors and hubs ensure controlled access and PA support, cutting initiation delays and leveraging specialty drugs' ≈50% share of US drug spend (2023). IDN, dialysis and oncology formulary wins target concentrated sites (DaVita/Fresenius reach ~70% dialysis pts). MSLs/field teams drive HCP uptake across ~700M CKD population (2024). Digital portals enable eRx/real-time benefit checks (96% e-prescribing coverage, 2024).

Hospitals, IDNs, and clinics—including over 6,000 US hospitals and roughly 1,300 health systems—procure and manage formularies and clinical protocols to standardize care and control spend. They prioritize operational efficiency and outcomes, evaluate budget impact and pathway fit for new therapies, and favor vendors offering reliable supply chains and robust clinical/support services.

Nephrologists/dialysis providers (≈550,000 US dialysis patients; Medicare covers ~71%) drive CKD anemia prescribing and favor oral/less-frequent dosing and clear reimbursement. Hematologists/oncologists require robust phase 3/RWE for MDS/oncology anemia (incidence ~4/100,000). Payers/IDNs demand HEOR and total-cost evidence (US health spend ≈18% GDP, 2024); patients (WHO: 1.74B anemic) prioritize oral/home care, adherence ~50%.

API synthesis, formulation and QA/QC drive FibroGen’s COGS, aligning with 2024 biologics norms where manufacturing accounts for ~20–40% of product cost. Tech transfers and validation runs incur program-specific expenses typically in the $0.5–5M range per asset in 2024. Maintaining redundant suppliers added roughly 5–10% to manufacturing spend, while packaging and distribution contributed an additional 2–6% of COGS.

Preclinical R&D (~$187M in 2024) and translational science drive core costs; Phase 3 programs often run $150–300M. Manufacturing/COGS align with biologics norms at ~20–40% of product cost. Partner upfronts/milestones (5–150M; 50M–1B) and royalties (5–20%) materially affect cash flow.

Upfronts and milestone payments—seen in FibroGen’s alliances with Astellas and AstraZeneca—deliver cash on signing and at development, regulatory, and sales milestones, smoothing funding needs during long trials; industry milestones often occur in staged payments reaching into the tens of millions. Milestones validate asset progress and enable deal structures that diversify funding sources and de‑risk pipelines.

Net sales from Evrenzo drive top-line revenue; market expansion depends on dialysis vs non-dialysis uptake and partner-led launches (2024: Astellas, AstraZeneca).

Licensing yields upfronts and milestones (commonly in the tens of millions) plus royalties; typical 2024 royalty bands reported at 8–20%.

Grants and co-promotion splits provide non‑dilutive funding and lower precommercial burn.